Please see full Prescribing Information for AREXVY. About SHINGRIX (Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Parade on MSN6d
Want To Lower Your Dementia Risk? Don’t Skip This VaccineIt’s easy to see how vaccines for health conditions that don’t make headlines as much as COVID or the flu (which everyone ...
About one in three people will develop shingles in their lifetime and nearly all adults aged 50 years and older carry the inactive virus that causes it. But the the risk of develo ...
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
Researchers conducted an observational study to compare the risk for dementia associated with both the live and recombinant shingles vaccines.
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback